Novavax (NVAX) - 21.80% Below 52-Week High: Buy or Wait?

Stock Details

Novavax, Inc. (NVAX), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $9.36. Over the past 52 weeks, it has ranged between $6.20 and $11.97. This places the current price at 78.2% of its 52-week high and 51.0% above its 52-week low. Recent trading volume was recorded at 1,421. The 14-day Relative Strength Index (RSI) stands at 51.15, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $9.18 by 1.96%. Similarly, it is above its 200-day moving average of $8.53 by 9.73%. The MACD histogram is 0.05, indicating bullish momentum (MACD Line: 0.01, Signal Line: -0.04). There is currently 1 active alert set for NVAX by users.

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

-17.23

PEG Ratio

1.32

Reasonably valued

EV/EBITDA

17.51

EPS (TTM)

-$0.56

Price to Sales

2.58

Beta

2.43

More volatile than market

Q:How is NVAX valued relative to its earnings and growth?

Valuation data is not available for this stock.

Q:What is NVAX's risk profile compared to the market?

With a beta of 2.43, Novavax, Inc. is significantly more volatile than the market. For every 10% market move, this stock tends to move 24% in the same direction. Higher beta stocks offer greater potential returns but with increased risk.

Performance & Growth

Profit Margin

-14.73%

Operating Margin

-7.19%

EBITDA

$59.53M

Return on Assets

1.99%

Revenue Growth (YoY)

-79.10%

Q:How profitable and efficient is NVAX's business model?

Novavax, Inc. achieves a profit margin of -14.73%, meaning it retains $-14.73 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -7.19% reveals how efficiently the company runs its core business operations before interest and taxes.

Q:What are NVAX's recent growth trends?

Novavax, Inc.'s revenue declined by 79.10% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$1.5B

Revenue (TTM)

$596.34M

Revenue/Share (TTM)

$3.67

Shares Outstanding

164.44M

Book Value/Share

-$0.88

Asset Type

EQUITY

Q:What is NVAX's market capitalization and position?

Novavax, Inc. has a market capitalization of $1.5B, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 164.44M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.

Q:How does NVAX's price compare to its book value?

Novavax, Inc.'s book value per share is -$0.88, while the current stock price is $9.36, resulting in a price-to-book (P/B) ratio of -10.64. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$14.11

50.78% upside potential

Analyst Recommendations

Strong Buy

Buy

Hold

Sell

Strong Sell

Q:How reliable are analyst predictions for NVAX?

9 analysts cover NVAX with 56% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $14.11 implies 50.8% upside, but targets are often adjusted to follow price moves rather than predict them.

Q:What is the Wall Street consensus on NVAX?

Current analyst recommendations:05 Buy, 1 Hold, 1 Sell, 2 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 7, 2026, 02:08 AM

Technical Indicators

RSI (14-day)

51.15

Neutral

50-Day Moving Average

$9.18

1.96% above MA-50

200-Day Moving Average

$8.53

9.73% above MA-200

MACD Line

0.01

MACD Signal

-0.04

MACD Histogram

0.05

Bullish

Q:What does NVAX's RSI value tell investors?

The RSI (Relative Strength Index) for NVAX is currently 51.15, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being above the 50-day moving average, this confirms bullish conditions.

Q:How should traders interpret NVAX's MACD and moving average crossovers?

MACD analysis shows the MACD line at 0.01 above the signal line at -0.04, with histogram at 0.05. This bullish crossover suggests upward momentum is building. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($9.18) is above the 200-day MA ($8.53), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Jul 7, 2026, 12:55 AM

Condition	Threshold	Created At
Price decreases by	7%	Jul 2, 2026, 04:10 PM

Condition

Threshold

Created At

Price decreases by

Jul 2, 2026, 04:10 PM

Novavax, Inc. (NVAX) Stock